Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators

Division of Cardiology, University of Texas Medical School, Houston 77030.

OBJECTIVES. This study examined the relation between neurohumoral activation and severity of left ventricular dysfunction and congestive heart failure in a broad group of patients with depressed left ventricular function who were not recruited on the basis of eligibility for a therapeutic trial. BACKGROUND. Previous studies have established the presence of neurohumoral activation in patients with severe congestive heart failure. It is not known whether the activation of these neurohumoral mechanisms is related to an impairment in left ventricular function. METHODS. From the 6,273 patients recruited into the Studies of Left Ventricular Dysfunction Registry (SOLVD), a subgroup of 859 patients were randomly selected, and their plasma norepinephrine, plasma renin activity, arginine vasopressin and atrial natriuretic peptide levels were correlated with clinical findings, New York Heart Association functional class, left ventricular ejection fraction and drug use. RESULTS. There was a weak but significant correlation between ejection fraction and an increase in plasma norepinephrine (rho = -0.18, p < 0.0001), plasma renin activity (rho = -0.24, p < 0.0001) and arginine vasopressin (rho = -0.12, p < 0.003). The only exception was atrial natriuretic peptide, which showed the best correlation to ejection fraction (rho = -0.37, p < 0.0001). Deterioration in functional class was associated more with increases in atrial natriuretic peptide (p = 0.0003) and plasma renin activity (p = 0.0003) and less with an increase in plasma norepinephrine. Of the clinical variables, elevated jugular venous pressure and third heart sound (S3) gallop were significantly associated with increased levels of plasma norepinephrine, plasma renin activity and atrial natriuretic peptide. We then compared the relation of neurohormones with clinical signs, functional status, ejection fraction and drug therapy and controlled for mutual interactive effects. After adjustment, a decrease in ejection fraction was still significantly related to an increase in plasma norepinephrine, plasma renin activity and atrial natriuretic peptide. In contrast, only a difference between functional classes I and III/IV was associated with an increase in plasma renin activity and atrial natriuretic peptide levels. CONCLUSIONS. Neurohumoral activation in patients with heart failure is related to severity of left ventricular functional depression, and this relation is independent of functional class or concomitant drug therapy.

This article has been cited by other articles:

				W. S. Colucci, T. J. Kolias, K. F. Adams, W. F. Armstrong, J. K. Ghali, S. S. Gottlieb, B. Greenberg, M. I. Klibaner, M. L. Kukin, J. E. Sugg, et al. Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial Circulation, July 3, 2007; 116(1): 49 - 56. [Abstract] [Full Text] [PDF]

				M. Rienstra, I. C. Van Gelder, M. P. Van den Berg, F. Boomsma, and D. J. Van Veldhuisen Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP Europace, July 1, 2006; 8(7): 482 - 487. [Abstract] [Full Text] [PDF]

				K. K. Teo, L. B. Mitchell, J. Pogue, J. Bosch, G. Dagenais, S. Yusuf, and on behalf of the HOPE Investigators Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction Circulation, September 14, 2004; 110(11): 1413 - 1417. [Abstract] [Full Text] [PDF]

				L. Menezes Falcao, F. Pinto, L. Ravara, and P. A. van Zwieten BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction Journal of Renin-Angiotensin-Aldosterone System, September 1, 2004; 5(3): 121 - 129. [Abstract] [PDF]

				R. Latini, S. Masson, I. Anand, M. Salio, A. Hester, D. Judd, S. Barlera, A. P Maggioni, G. Tognoni, J. N Cohn, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT Eur. Heart J., February 2, 2004; 25(4): 292 - 299. [Abstract] [Full Text] [PDF]

				G. Grassi, G. Seravalle, F. Quarti-Trevano, R. Dell'Oro, G. Bolla, and G. Mancia Effects of Hypertension and Obesity on the Sympathetic Activation of Heart Failure Patients Hypertension, November 1, 2003; 42(5): 873 - 877. [Abstract] [Full Text] [PDF]

				S. Gattenlohner, C. Waller, G. Ertl, B.-D. Bultmann, H.-K. Muller-Hermelink, and A. Marx NCAM(CD56) and RUNX1(AML1) Are Up-Regulated in Human Ischemic Cardiomyopathy and a Rat Model of Chronic Cardiac Ischemia Am. J. Pathol., September 1, 2003; 163(3): 1081 - 1090. [Abstract] [Full Text] [PDF]

				P. B. Adamson, K. J. Kleckner, W. L. VanHout, S. Srinivasan, and W. T. Abraham Cardiac Resynchronization Therapy Improves Heart Rate Variability in Patients with Symptomatic Heart Failure Circulation, July 22, 2003; 108(3): 266 - 269. [Abstract] [Full Text] [PDF]

				R. Latini, S. Masson, I. Anand, D. Judd, A. P. Maggioni, Y.-T. Chiang, M. Bevilacqua, M. Salio, P. Cardano, P. H.J.M. Dunselman, et al. Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) Circulation, November 5, 2002; 106(19): 2454 - 2458. [Abstract] [Full Text] [PDF]

				N. Sivasubramanian, M. L. Coker, K. M. Kurrelmeyer, W. R. MacLellan, F. J. DeMayo, F. G. Spinale, and D. L. Mann Left Ventricular Remodeling in Transgenic Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor Circulation, August 14, 2001; 104(7): 826 - 831. [Abstract] [Full Text] [PDF]

				A. Rossi, M. Enriquez-Sarano, J. C. Burnett Jr., A. Lerman, M. D. Abel, and J. B. Seward Natriuretic peptide levels in atrial fibrillation: A prospective hormonal and Doppler-echocardiographic study J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1256 - 1262. [Abstract] [Full Text] [PDF]

				Z. Dibbs, J. Thornby, B. G. White, and D. L. Mann Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials J. Am. Coll. Cardiol., June 1, 1999; 33(7): 1935 - 1942. [Abstract] [Full Text] [PDF]

				K. Yamamoto, U. Ikeda, K. Okada, T. Saito, Y. Kawahara, M. Okuda, M. Yokoyama, and K. Shimada Arginine Vasopressin Increases Nitric Oxide Synthesis in Cytokine-Stimulated Rat Cardiac Myocytes Hypertension, November 1, 1997; 30(5): 1112 - 1120. [Abstract] [Full Text]

				C. R. Benedict, B. Shelton, D. E. Johnstone, G. Francis, B. Greenberg, M. Konstam, J. L. Probstfield, and S. Yusuf Prognostic Significance of Plasma Norepinephrine in Patients With Asymptomatic Left Ventricular Dysfunction Circulation, August 15, 1996; 94(4): 690 - 697. [Abstract] [Full Text]

				G. Grassi, G. Seravalle, B. M. Cattaneo, A. Lanfranchi, S. Vailati, C. Giannattasio, A. Del Bo, C. Sala, G. B. Bolla, M. Pozzi, et al. Sympathetic Activation and Loss of Reflex Sympathetic Control in Mild Congestive Heart Failure Circulation, December 1, 1995; 92(11): 3206 - 3211. [Abstract] [Full Text]

				K. Swedberg, M. R. Bristow, J. N. Cohn, H. Dargie, M. Straub, C. Wiltse, T. J. Wright, and for the Moxonidine Safety and Efficacy (MOXSE) Inv Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart Failure Circulation, April 16, 2002; 105(15): 1797 - 1803. [Abstract] [Full Text] [PDF]